Close Menu

NEW YORK – Veracyte said after the close of the market on Thursday that it expects preliminary Q1 revenues to be in the range of $30.5 million to $31.5 million.

The expected revenues would represent a range of 3 to about 7 percent increase from $29.5 million a year ago and would beat the analysts' average estimate of $30.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.